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Human platelet concentrates are usually stored in blood banks for 5 
days, after expiration date they are discarded. Human lyophilized 
platelet is one of the approaches to preserve the platelets for long time 
storage. In our study trehalose was used as a stabilizer to protect the 
platelets during freezing and drying conditions.Platelet rich plasma was 
prepared as a source of platelet concentrate.Washed platelets were 
incubated in the presence of  trehalose (40 mM /l) trehalose for 4 h at 
37°C. After lyophilization. prehydration  and rehydration stages, the 
response of lyophilized human platelets to the agonists such as ADP, 
ristositin and arachidonic acid  were measured by an aggregometer 
instrument. Aggregation of platelets with ADP, ristositin and 
arachidonic acid  showed 75.5%, 55.9% and 17.3% activity respectively. 
Clot formation at 37°C was clearly observed within 5 min after addition 
of these agonists to rehydrated lyophilized platelets.Our study showed 
that this method of preserving platelets with internal trehalose loading  is 
possible in the dried state for storage at room temperature but for  its 
quality improvement further investigation is required. 
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Introduction 
Platelets are component of the blood that are 
critical for maintenance of hemostasis. They play 
an essential role to clot formation, wound healing 
and proper maintenance of blood vessels. Blood 
transfusion centers are under considerable 
pressure to produce platelets concentration for 
transfusion.  Due to the short life span of human 
platelets using standard blood banking procedure, 
currently at 22°C in most blood banks, human 
platelets are maintained in liquid solutions at 
room temperature for only 5 days and then 
thrown away if not transfused within that period. 
Many approaches have been investigated 
experimentally to produce new hemostatically 
active platelet products that are capable of long-
term storage [1-6]. Lyophilized platelet product 
which is one of the best choice can play a critical 
role in treatment of tendonitis [7], wound healing  
 
[8], hepatocyte proliferation [9] and control 
bleeding in animals [10-13]. 
 
The use of protective carbohydrate for preserving 
platelets during lyophilization has been 
investigated before in response to environmental 
stressors including chilling, freezing and drying 
[14-17]. Carbohydrates such as trehalose which is 
found at high concentration in a wide variety of 
organisms have an especial ability to stabilize 
platelets during freeze-drying process [17-18]. 
The principle mechanism of preservation during 
freezing and drying stress is mediated by direct 
bonding of the hydroxyl groups of these 
carbohydrates to membrane surfaces with 
creating water replacement structure that holds 
native conformation in place [18].  
   





In this paper we describe platelet lyophilization 
process by using trehalose as a stabilizer to 
prepare functional freeze-dried platelets with 
aggregation capability.  
 
Materials and Methods 
Materials 
Sodium chloride, potassium chloride, magnesium 
chloride, imidazole and HEPES were supplied 
from Merck Co. (Germany). Human serum 
albumin solution 20% was obtained from Biotest 
(Germany). Prostaglandin E1 and EGTA were 
purchased from Sigma-Aldrich (USA). All 
chemicals were of analytical grade. Human serum 
albumin was used without further purification. 
 
Methods 
Platelet Rich Plasma Preparation 
Whole blood was obtained from Vesal Blood 
Transfusion Center (Vesal, Tehran) and then  
Platelet rich plasma (PRP) was prepared  by 
centrifugation (2050 g, 4 min) and aggregation 
tests were performed as soon as possible. 
 
Lyophilization process 
 PRP was centrifuged for 5 min at 500 g to 
remove leukocytes. The supernatant containing 
platelet was washed (600 g, 10 min) with 
washing  buffer (100 mmol/L NaCl, 10 mmol/L 
KCl, 10 mmol/L EGTA, 10 mmol/L Imidazol, 10 
μg/mL PGE1, pH:6.8). Washed platelet in a 
concentration of 0.8-1x10 9 plt/mL were 
incubated at 37°C for 4 h in loading buffer 
(washing buffer in the presence of 40 mmol/L 
trehalose). The samples were stirred every 1 h 
during incubation.  Platelets were pelleted and 
resuspended in lyophilization buffer (9.5 mmol/L 
Hepes,142.5 mmol/L NaCl, 4.8 mmol/L KCl, 
1mmol/L MgCl2, 30 mmol/L Trehalose, 1% 
human serum albumin, pH:6.8). Platelet 
concentrates were transferred in freezer -80C° 
with freezing rate -1C°/min for 90 minutes. After 
freezing, the frozen  platelet solution were 
transferred to lyophilizator (VaCo 5-II, Zirbus 
Technology) under100 mili Torr vaccum pressure 
for 16 h. Freeze dried platelet concentrates were 
prehydrated for approximately 2 hours in a closed 
box with moisture-saturated air at 37°C. Vials 
containing freeze dried platelet rehydrated in 4 ml 
platelet poor plasma/water (2/1v/v). 
 
Aggregation tests 
 For aggregation tests platelet suspension were 
transferred to aggregation cuvettes with a 
magnetic stirrer and response of the platelet to the 
ADP, Ristositin and Arachidonic Acid agonists 
were measured by Helena aggrigometer under 
stirring condition within 5 min.    
 
Results and Discussions  
Response of Platelets to Platelet Agonists 
The aggregation of PRP by adding ADP, 
arachidonic acid and ristocetin agonists was 
measured by aggregometry with the activity of 
70.5%, 89.5% and 82.3% while aggregation 
activity in rehydrated lyophilized platelet was 
found 75.5, 55.9 and 17.3% respectively. 
 
The results of aggregation tests for PRP and 
rehydrated lyophilized platelet at standard agonist 
concentrations were summarized in table I. 
According to these results, response of rehydrated 
lyophilized platelet to the agonists were lower 
than PRP that was used as a starting material. We 
did not find any reason, why ristocetin response 
was the lowest. In general it seems that, freezing, 
drying and rehydration steps can lower 
membrane aggregability of platelet during 
lyophilization process, but the platelets have 
retained their aggregation properties somedeal.  
 
Table 1.  Platelet aggregation test results (%) of platelet rich plasma and rehydrated lyophilized platelet with various agonists. 
 
  Ty       pe of agonist                 ADP          Arachidonic acid             Ristocetin     
Platelet rich plasma                             89.5                      70.5                               88.2           
Rehydrated lyophilized  platelet           75.5                      55.9                                17.3 
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Clot Formation 
Clot formation at 37°C was clearly observed 
within 5 min after addition of these agonists to 
rehydrated lyophilized platelets. Furthermore, 
when the supernatant was measured with the 
Coulter counter, we found that no platelets were 
left in suspension. This indicated that all platelets 
participated in platelet aggregates formation. 
 
Trehalose Uptake by Platelets   
The findings of this study supported our 
hypothesis that rehydrated freeze-dried platelet 
concentrate is functional and can respond to the 
various agonists during aggregation tests. In oue  
experiment trehalose-loaded platelets were 
successfully freeze-dried, with relatively favorite 
recovery of intact platelets. Of course there is a 
major challenge to introduce sugar into the cell at 
high concentration. Current efforts helped at 
solving this problem include: (1) biosynthesis of 
trehalose by expression of trehalose genes in cells 
[18], (2) with creation of pores in the membrane 
[19], (3) taking advantage of the high 
permeability of membranes at the phase transition 
temperature [20], (4) introducing trehalose into 
the cytosol of human platelets with endocytosis 
pathway at higher temperature (above 25°C) 
which was discovered as a simple method by 
Wolkers et al [15]. In our study this simple 
method was used and platelets were loaded in the 
presence of 40 mM external trehalose at 37°C for 
4 h. With this method trehalose is rapidly taken 
up by human platelets with loading efficiencies of  
50%  or greater [15]. 
   
Prehydration and Rehydration Step 
The beneficial effects of pre-hydration and 
rehydration steps have been well studied [21-24]. 
According to the recent study [24], 1.5 h of 
prehydration had better effect than 3.5 h and there 
was no difference between 35°C and 37°C in 
preyhdration temperature. This study also showed 
that platelet poor plasma behaved better than 
phosphate-buffer saline as a rehydration solution. 
In our study, samples were settled in 2 h at 37°C 
during prehydration step and reconstituted with 




The findings of this study supported our 
hypothesis that rehydrated freeze-dried platelet 
concentrate is functional and can respond to the 
various agonists during aggregation tests. 
In general, our study showed that this method of 
preserving platelets in the dried state is possible 
for storage at room temperature with using 
Iranian PRP units. However, trehalose loading 
efficiency, lyophilization process and proper 
storage conditions of the freeze-dried platelet 
need to be further investigated for optimizing 
process and improve aggregability of lyophilized 
platelet.    
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